Evidence map›Paper›PMID 35096256›Full record

ReviewThe Journal of clinical and aesthetic dermatology2021

Review on Novel Oral Therapies for Psoriasis.

Olga Marushchak, Rose Yakubov, Rebecca Yakubov, Gary Goldenberg

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.Recent advances in inflammation & allergy drug discovery · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Olga MarushchakMs. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount Sinai in New York, New York.
Rose YakubovMs. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount Sinai in New York, New York.
Rebecca YakubovMs. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount Sinai in New York, New York.
Gary GoldenbergMs. Marushchak and Dr. Goldenberg are with the Icahn School of Medicine at Mount Sinai in New York, New York.
Thrombosis and Atherosclerosis Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, several classes of oral therapies for psoriasis are in use, in development, or in investigative stages. Standard non-biologic treatments for psoriasis, such as methotrexate, cyclosporine, and acitretin, have generally unfavorable safety profiles and are not ideal for long-term use. This review will address the safety and efficacy of existing and novel oral therapies for psoriasis that target inflammatory pathways via modulation of phosphodiesterase 4 (PDE4), Janus kinases (JAKs), sphingosine 1-phosphate (S1P), A3 adenosine receptors, and rho-associated kinase 2 (ROCK2), with an emphasis on JAK inhibitors.

Indexed as

JAK inhibitorsnovel oral treatmentPsoriasis

Identifiers

PMID35096256
PMCPMC8794486
OpenAlexW4226503149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.